Perseus Proteomics Inc. (TYO:4882)

Japan flag Japan · Delayed Price · Currency is JPY
150.00
+1.00 (0.67%)
At close: Jul 9, 2026
Market Cap2.53B -58.3%
Revenue (ttm)135.00M +12.5%
Net Income-718.00M
EPS-48.17
Shares Out 17.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume120,800
Open151.00
Previous Close149.00
Day's Range147.00 - 152.00
52-Week Range142.00 - 425.00
Beta0.32
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;... [Read more]

Sector Healthcare
Founded 2001
Employees 35
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4882
Full Company Profile

Financial Performance

In fiscal year 2026, Perseus Proteomics's revenue was 135.00 million, an increase of 12.50% compared to the previous year's 120.00 million. Losses were -718.00 million, -20.58% less than in 2025.

Financial Statements